

Clinical trials of triflusal+coumadin medium dose

TrialResults-center www.trialresultscenter.org

1 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
triflusal+coumadin medium dose vs coumadin standard dose			
NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose) , 2004 n=235/237 follow-up: 2.76 years	Triflusal 600 mg/d + coumadin medium dose (target INR 1.25-2) versus coumadin standard dose(target INR 2-3)	Non valvular atrial fibrillation. Intermediate risk patients.	Parallel groups Open Spain
triflusal+coumadin medium dose vs triflusal			
NASPEAF (triflusal+coumadin medium dose vs triflusal) , 2004 n=235/242 follow-up: 2.76 years	Triflusal 600 mg/d + coumadin medium dose (target INR 1.25-2) versus Triflusal 600 mg/d	Non valvular atrial fibrillation. Intermediate risk patients	Parallel groups Open Spain

More details and results :

- antithrombotics for atrial fibrillation in primary prevention of thromboembolic events at <http://www.trialresultscenter.org/go-Q57>

References

NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004:

Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, Mataix L Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004 Oct 19;44:1557-66 [[15489085](#)]

NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004:

Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, Mataix L Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004 Oct 19;44:1557-66 [[15489085](#)]